{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:07:17Z","timestamp":1793704037136,"version":"4.5.1"},"reference-count":180,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med. Technol."],"abstract":"<jats:p>Dengue infections still have a tremendous impact on public health systems in most countries in tropical and subtropical regions. The disease is systemic and dynamic with broad range of manifestations, varying from mild symptoms to severe dengue (Dengue Hemorrhagic Fever and Dengue Shock Syndrome). The only licensed tetravalent dengue vaccine, Dengvaxia, is a chimeric yellow fever virus with prM and E genes from the different dengue serotypes. However, recent results indicated that seronegative individuals became more susceptible to develop severe dengue when infected after vaccination, and now WHO recommends vaccination only to dengue seropositive people. One possibility to explain these data is the lack of robust T-cell responses and antibody-dependent enhancement of virus replication in vaccinated people. On the other hand, DNA vaccines are excellent inducers of T-cell responses in experimental animals and it can also elicit antibody production. Clinical trials with DNA vaccines have improved and shown promising results regarding the use of this approach for human vaccination. Therefore, in this paper we review preclinical and clinical tests with DNA vaccines against the dengue virus. Most of the studies are based on the E protein since this antigen is the main target for neutralizing antibody production. Yet, there are other reports with DNA vaccines based on non-structural dengue proteins with protective results, as well. Combining structural and non-structural genes may be a solution for inducing immune responses aging in different infection moments. Furthermore, DNA immunizations are also a very good approach in combining strategies for vaccines against dengue, in heterologous prime\/boost regimen or even administering different vaccines at the same time, in order to induce efficient humoral and cellular immune responses.<\/jats:p>","DOI":"10.3389\/fmedt.2021.640964","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T04:56:23Z","timestamp":1618203383000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?"],"prefix":"10.3389","volume":"3","author":[{"given":"Ada Maria Barcelos","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Morais","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolla Beatriz Almeida","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1471-2334-11-106","article-title":"Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries","volume":"11","author":"Barniol","year":"2011","journal-title":"BMC Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1016\/j.vaccine.2017.09.089","article-title":"Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age","volume":"35","author":"Halstead","year":"2017","journal-title":"Vaccine."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum Vaccines Immunother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e83386","DOI":"10.1371\/journal.pone.0083386","article-title":"The pathology of severe dengue in multiple organs of human fatal cases: histopathology, ultrastructure and virus replication","volume":"9","author":"P\u00f3voa","year":"2014","journal-title":"PLoS ONE."},{"key":"B7","doi-asserted-by":"publisher","first-page":"29201","DOI":"10.1038\/srep29201","article-title":"Antibody-dependent enhancement of dengue virus infection in primary human macrophages; balancing higher fusion against antiviral responses","volume":"6","author":"Flipse","year":"2016","journal-title":"Sci Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s12879-018-3603-x","article-title":"Heart and liver are infected in fatal cases of dengue: three PCR based case studies","volume":"18","author":"Kularatne","year":"2018","journal-title":"BMC Infect Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/femsre\/fuu004","article-title":"Receptors and routes of dengue virus entry into the host cells","volume":"39","author":"Cruz-Oliveira","year":"2015","journal-title":"FEMS Microbiol Rev."},{"key":"B10","volume-title":"Flaviviridae: The Viruses and Their Replication","author":"Lindenbach","year":"2006"},{"key":"B11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature02165","article-title":"Structure of the dengue virus envelope protein after membrane fusion","volume":"427","author":"Modis","year":"2004","journal-title":"Nature."},{"key":"B12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.15252\/embr.201745302","article-title":"The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design","volume":"19","author":"Rey","year":"2018","journal-title":"EMBO Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.str.2004.06.019","article-title":"Conformational changes of the flavivirus E glycoprotein","volume":"12","author":"Zhang","year":"2004","journal-title":"Structure."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.4049\/jimmunol.176.5.2825","article-title":"The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection","volume":"176","author":"Huang","year":"2006","journal-title":"J Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science."},{"key":"B16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/bip.22266","article-title":"Peptides as models for the structure and function of viral capsid proteins: insights on dengue virus capsid: peptides for the structure and function of viral capsid proteins","volume":"100","author":"Freire","year":"2013","journal-title":"Biopolymers."},{"key":"B17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/pathogens9010042","article-title":"Understanding flavivirus capsid protein functions: the tip of the iceberg","volume":"9","author":"Sotcheff","year":"2020","journal-title":"Pathogens."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.1128\/JVI.73.7.6104-6110.1999","article-title":"Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion","volume":"73","author":"Flamand","year":"1999","journal-title":"J Virol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1096\/fj.99-0829com","article-title":"Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction","volume":"14","author":"Jacobs","year":"2000","journal-title":"FASEB J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1128\/JCM.38.3.1053-1057.2000","article-title":"An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients","volume":"38","author":"Young","year":"2000","journal-title":"J Clin Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1006\/viro.1996.0307","article-title":"Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication","volume":"220","author":"Mackenzie","year":"1996","journal-title":"Virology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1128\/JVI.73.6.4611-4621.1999","article-title":"Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function","volume":"73","author":"Lindenbach","year":"1999","journal-title":"J Virol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7360","DOI":"10.1128\/JVI.00157-12","article-title":"Evidence for a genetic and physical interaction between nonstructural proteins NS1 and NS4B that modulates replication of West Nile virus","volume":"86","author":"Youn","year":"2012","journal-title":"J Virol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-virology-101416-041848","article-title":"The good, the bad, and the shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis","volume":"5","author":"Glasner","year":"2018","journal-title":"Annu Rev Virol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.dib.2016.11.083","article-title":"Dataset of proteins mapped on HepG2 cells and those differentially abundant after expression of the dengue non-structural 1 protein","volume":"10","author":"Rabelo","year":"2017","journal-title":"Data Brief."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1086\/500949","article-title":"Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement","volume":"193","author":"Avirutnan","year":"2006","journal-title":"J Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s007050050127","article-title":"The dengue virus nonstructural-1 protein (NS1) generatesantibodies to common epitopes on human blood clotting, integrin\/adhesin proteins and binds to humanendothelial cells: potential implications in haemorrhagic fever pathogenesis","volume":"142","author":"Falconar","year":"1997","journal-title":"Arch Virol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"12225","DOI":"10.1128\/JVI.78.22.12225-12235.2004","article-title":"Analysis of adaptive mutations in kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription","volume":"78","author":"Liu","year":"2004","journal-title":"J Virol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1128\/JVI.67.4.2034-2042.1993","article-title":"Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity","volume":"67","author":"Falgout","year":"1993","journal-title":"J Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1745-7270.2008.00382.x","article-title":"Biological characteristics of dengue virus and potential targets for drug design","volume":"40","author":"Qi","year":"2008","journal-title":"Acta Biochim Biophys Sin."},{"key":"B31","doi-asserted-by":"publisher","first-page":"12904","DOI":"10.1093\/nar\/gkx1127","article-title":"NS3 helicase from dengue virus specifically recognizes viral RNA sequence to ensure optimal replication","volume":"45","author":"Swarbrick","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8873","DOI":"10.1074\/jbc.M609919200","article-title":"The Non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner","volume":"282","author":"Miller","year":"2007","journal-title":"J Biol Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"22147","DOI":"10.1074\/jbc.M110.192500","article-title":"Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication","volume":"286","author":"McLean","year":"2011","journal-title":"J Biol Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1099\/vir.0.81844-0","article-title":"Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA","volume":"87","author":"Umareddy","year":"2006","journal-title":"J Gen Virol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/v9040091","article-title":"Dengue virus non-structural protein 5","volume":"9","author":"Sahili","year":"2017","journal-title":"Viruses."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1371\/journal.pntd.0000617","article-title":"Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006","volume":"4","author":"Fried","year":"2010","journal-title":"PLoS Negl Trop Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00281-017-0625-1","article-title":"Immune-mediated cytokine storm and its role in severe dengue","volume":"39","author":"Srikiatkhachorn","year":"2017","journal-title":"Semin Immunopathol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.actatropica.2015.04.023","article-title":"Circulating cytokines and chemokines associated with plasma leakage and hepatic dysfunction in Brazilian children with dengue fever","volume":"149","author":"Ferreira","year":"2015","journal-title":"Acta Trop."},{"key":"B40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/jir.2017.0037","article-title":"Highlights for dengue immunopathogenesis: antibody-dependent enhancement, cytokine storm, and beyond","volume":"38","author":"Kuczera","year":"2018","journal-title":"J Interferon Cytokine Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.239.4839.476","article-title":"Pathogenesis of dengue: challenges to molecular biology","volume":"239","author":"Halstead","year":"1988","journal-title":"Science."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(07)61687-0","article-title":"Dengue","volume":"370","author":"Halstead","year":"2007","journal-title":"Lancet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1099\/vir.0.82537-0","article-title":"Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells","volume":"88","author":"Chareonsirisuthigul","year":"2007","journal-title":"J Gen Virol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"572681","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-Dependent Enhancement: a challenge for developing a safe dengue vaccine","volume":"10","author":"Shukla","year":"2020","journal-title":"Front Cell Infect Microbiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1600-065X.2008.00678.x","article-title":"Understanding the contribution of cellular immunity to dengue disease pathogenesis","volume":"225","author":"Mathew","year":"2008","journal-title":"Immunol Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcv.2017.10.010","article-title":"Characterization of type I interferon responses in dengue and severe dengue in children in Paraguay","volume":"97","author":"Talarico","year":"2017","journal-title":"J Clin Virol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nm887","article-title":"Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever","volume":"9","author":"Mongkolsapaya","year":"2003","journal-title":"Nat Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.4049\/jimmunol.0903262","article-title":"Timing of CD8 + T cell responses in relation to commencement of capillary leakage in children with Dengue","volume":"184","author":"Dung","year":"2010","journal-title":"J Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1289\/ehp.1509981","article-title":"Three-month real-time dengue forecast models: an early warning system for outbreak alerts and policy decision support in Singapore","volume":"124","author":"Shi","year":"2016","journal-title":"Environ Health Perspect."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1742","DOI":"10.1371\/journal.pntd.0001742","article-title":"Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans","volume":"6","author":"Lindow","year":"2012","journal-title":"PLoS Negl Trop Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s13071-020-04334-5","article-title":"Assessing the vertical transmission potential of dengue virus in field-reared Aedes aegypti using patient-derived blood meals in Ho Chi Minh City, Vietnam","volume":"13","author":"Goncalves","year":"2020","journal-title":"Parasit Vectors."},{"key":"B53","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1016\/j.vaccine.2020.03.029","article-title":"Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus","volume":"38","author":"Dayan","year":"2020","journal-title":"Vaccine."},{"key":"B55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/infdis\/jiw068","article-title":"Dengue vaccine: the need, the challenges, and progress","volume":"214","author":"Rothman","year":"2016","journal-title":"J Infect Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/vaccines8010063","article-title":"A review on dengue vaccine development","volume":"8","author":"Deng","year":"2020","journal-title":"Vaccines."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/v3101800","article-title":"Next-generation dengue vaccines: novel strategies currently under development","volume":"3","author":"Durbin","year":"2011","journal-title":"Viruses."},{"key":"B58","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.2147\/IJN.S49972","article-title":"Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus","volume":"8","author":"Huang","year":"2013","journal-title":"Int J Nanomed."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomized, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e2001894","DOI":"10.1371\/journal.pbio.2001894","article-title":"Local introduction and heterogeneous spatial spread of dengue-suppressing Wolbachia through an urban population of Aedes aegypti","volume":"15","author":"Schmidt","year":"2017","journal-title":"PLoS Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4269\/ajtmh.17-0627","article-title":"Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico","volume":"98","author":"Diaz","year":"2018","journal-title":"Am J Trop Med Hyg."},{"key":"B63","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.1016\/j.vaccine.2011.07.021","article-title":"The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease","volume":"29","author":"Coller","year":"2011","journal-title":"Vaccine."},{"key":"B64","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1016\/j.vaccine.2015.09.101","article-title":"Preclinical and clinical development of a dengue recombinant subunit vaccine","volume":"33","author":"Manoff","year":"2015","journal-title":"Vaccine."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum Vaccines Immunother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jviromet.2009.04.011","article-title":"Application of antibodies against nonstructural protein 2B of dengue serotype 2 virus induced by DNA immunisation or recombinant protein NS 2B immunisation in BALB\/c mice","volume":"163","author":"Liu","year":"2010","journal-title":"J Virol Methods."},{"key":"B67","doi-asserted-by":"publisher","first-page":"571030","DOI":"10.3389\/fmedt.2020.571030","article-title":"Harnessing recent advances in synthetic DNA and electroporation technologies for rapid vaccine development against COVID-19 and other emerging infectious diseases","volume":"2","author":"Xu","year":"2020","journal-title":"Front Med Technol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future: the past and future of DNA vaccines","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol Rev."},{"key":"B69","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev Vaccines."},{"key":"B70","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/hmg\/1.6.363","article-title":"Long-term persistence of plasmid DNA and foreign gone expression in mouse muscle","volume":"1","author":"Wolff","year":"1992","journal-title":"Hum Mol Genet."},{"key":"B71","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/sj.gt.3302213","article-title":"Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation","volume":"11","author":"Wang","year":"2004","journal-title":"Gene Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/vaccines7020037","article-title":"A comparison of plasmid DNA and mRNA as vaccine technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccines."},{"key":"B73","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2460\/javma.2005.226.240","article-title":"Immunologic responses to West Nile virus in vaccinated and clinically affected horses","volume":"226","author":"Davidson","year":"2005","journal-title":"J Am Vet Med Assoc."},{"key":"B74","unstructured":"DRAFT Landscape of Novel Coronavirus Candidate Vaccine Development Worldwide2020"},{"key":"B75","doi-asserted-by":"publisher","first-page":"608460","DOI":"10.3389\/fimmu.2020.608460","article-title":"RNA vaccines: a suitable platform for tackling emerging pandemics?","volume":"11","author":"Sandbrink","year":"2020","journal-title":"Front Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3389\/fimmu.2019.01424","article-title":"A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice","volume":"10","author":"Roth","year":"2019","journal-title":"Front Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature."},{"key":"B78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.24272\/j.issn.2095-8137.2020.016","article-title":"Long-term protection against dengue viruses in mice conferred by a tetravalent DNA vaccine candidate","volume":"41","author":"Wang","year":"2020","journal-title":"Zool Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s007050050348","article-title":"Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses","volume":"143","author":"Porter","year":"1998","journal-title":"Arch Virol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1006\/viro.2001.1136","article-title":"Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF","volume":"290","author":"Raviprakash","year":"2001","journal-title":"Virology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1016\/S0264-410X(00)00105-5","article-title":"A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys","volume":"18","author":"Kochel","year":"2000","journal-title":"Vaccine"},{"key":"B82","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/S0264-410X(99)00570-8","article-title":"Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein","volume":"18","author":"Raviprakash","year":"2000","journal-title":"Vaccine."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.vaccine.2005.09.032","article-title":"Evaluation of immunity and protective efficacy of a dengue-3 premembrane and envelope DNA vaccine in Aotus nancymae monkeys","volume":"24","author":"Blair","year":"2006","journal-title":"Vaccine."},{"key":"B85","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.vaccine.2011.10.085","article-title":"Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine","volume":"30","author":"Porter","year":"2012","journal-title":"Vaccine."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1099\/0022-1317-81-7-1659","article-title":"Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques","volume":"81","author":"Raviprakash","year":"2000","journal-title":"J. Gen. Virol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg."},{"key":"B88","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0264-410X(00)00247-4","article-title":"Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice","volume":"19","author":"Jimenez","year":"2000","journal-title":"Vaccine"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0264-410X(99)00376-X","article-title":"A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice","volume":"18","author":"Konishi","year":"2000","journal-title":"Vaccine."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1016\/S0264-410X(03)00376-1","article-title":"Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice","volume":"21","author":"Konishi","year":"2003","journal-title":"Vaccine."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.vaccine.2005.11.002","article-title":"Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice","volume":"24","author":"Konishi","year":"2006","journal-title":"Vaccine."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1016\/j.vaccine.2004.12.028","article-title":"Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein","volume":"23","author":"Mota","year":"2005","journal-title":"Vaccine."},{"key":"B93","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.1016\/j.vaccine.2009.06.061","article-title":"Development of a novel DNA SynConTM tetravalent dengue vaccine that elicits immune responses against four serotypes","volume":"27","author":"Ramanathan","year":"2009","journal-title":"Vaccine."},{"key":"B94","doi-asserted-by":"publisher","first-page":"e20528","DOI":"10.1371\/journal.pone.0020528","article-title":"DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III","volume":"6","author":"Azevedo","year":"2011","journal-title":"PLoS ONE."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e58357","DOI":"10.1371\/journal.pone.0058357","article-title":"The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever\/dengue virus leads to strong protection against dengue","volume":"8","author":"Azevedo","year":"2013","journal-title":"PLoS ONE."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3389\/fimmu.2019.01522","article-title":"T Cell responses induced by DNA vaccines based on the DENV2 E and NS1 proteins in mice: importance in protection and immunodominant epitope identification","volume":"10","author":"Pinto","year":"2019","journal-title":"Front Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e0003947","DOI":"10.1371\/journal.pntd.0003947","article-title":"Dengue E protein domain III-based dna immunisation induces strong antibody responses to all four viral serotypes","volume":"9","author":"Poggianella","year":"2015","journal-title":"PLoS Negl Trop Dis."},{"key":"B98","first-page":"9","article-title":"Neutralizing antibody response and efficacy of novel recombinant tetravalent dengue DNA vaccine comprising envelope domain III in mice","volume":"42","author":"Kulkarni","year":"2017","journal-title":"IJMS."},{"key":"B99","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clim.2016.08.021","article-title":"Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection","volume":"171","author":"Chen","year":"2016","journal-title":"Clin Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fcimb.2017.00175","article-title":"Effective protection induced by a monovalent DNA vaccine against dengue virus (DV) serotype 1 and a bivalent DNA vaccine against DV1 and DV2 in mice","volume":"7","author":"Zheng","year":"2017","journal-title":"Front Cell Infect Microbiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12250-019-00090-8","article-title":"Electroporation-mediated immunization of a candidate DNA vaccine expressing dengue virus serotype 4 prM-E antigen confers long-term protection in mice","volume":"34","author":"Sheng","year":"2019","journal-title":"Virol Sin."},{"key":"B102","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fcimb.2020.00087","article-title":"Long-term protection elicited by a DNA vaccine candidate expressing the prM-E antigen of dengue virus serotype 3 in mice","volume":"10","author":"Feng","year":"2020","journal-title":"Front Cell Infect Microbiol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fimmu.2019.00059","article-title":"Dendritic cell targeting using a DNA vaccine induces specific antibodies CD4+ T cells to the dengue virus envelope protein domain III","volume":"10","author":"Zaneti","year":"2019","journal-title":"Front Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0264-410X(97)00215-6","article-title":"Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice","volume":"15","author":"Kochel","year":"1997","journal-title":"Vaccine."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/S0264-410X(03)00009-4","article-title":"Dengue 2 PreM-E\/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies","volume":"21","author":"Lu","year":"2003","journal-title":"Vaccine."},{"key":"B106","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0042-6822(03)00542-7","article-title":"Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys","volume":"315","author":"Raviprakash","year":"2003","journal-title":"Virology."},{"key":"B107","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.imlet.2014.08.005","article-title":"Variable effects of the co-administration of a GM-CSF-expressing plasmid on the immune response to flavivirus DNA vaccines in mice","volume":"162","author":"Chen","year":"2014","journal-title":"Immunol Lett."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.4161\/hv.21806","article-title":"A dengue DNA vaccine formulated with Vaxfectin \u00ae is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits","volume":"8","author":"Raviprakash","year":"2012","journal-title":"Hum Vaccines Immunother."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3389\/fimmu.2019.02125","article-title":"Human T cell response to dengue virus infection","volume":"10","author":"Tian","year":"2019","journal-title":"Front Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.vaccine.2006.09.059","article-title":"Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine","volume":"25","author":"Imoto","year":"2007","journal-title":"Vaccine."},{"key":"B111","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00705-008-0250-3","article-title":"A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge","volume":"153","author":"De Paula","year":"2008","journal-title":"Arch Virol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.micinf.2013.07.008","article-title":"Comparison of infection-neutralizing and -enhancing antibody balance induced by two distinct genotype strains of dengue virus type 1 or 3 DNA vaccines in mice","volume":"15","author":"Sjatha","year":"2013","journal-title":"Microbes Infect."},{"key":"B113","doi-asserted-by":"publisher","first-page":"357","DOI":"10.7883\/yoken.JJID.2014.313","article-title":"Immunogenicity of a candidate DNA vaccine based on the prM\/E genes of a dengue type 2 virus cosmopolitan genotype strain","volume":"68","author":"Putri","year":"2015","journal-title":"Jpn J Infect Dis."},{"key":"B114","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"De Alwis","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e00556","DOI":"10.1128\/JVI.00556-18","article-title":"Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy for dengue vaccine","volume":"92","author":"Tsai","year":"2018","journal-title":"J Virol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.vaccine.2005.07.100","article-title":"Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen","volume":"24","author":"Apt","year":"2006","journal-title":"Vaccine."},{"key":"B117","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.virol.2006.05.005","article-title":"A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques","volume":"353","author":"Raviprakash","year":"2006","journal-title":"Virology."},{"key":"B118","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fimmu.2012.00334","article-title":"Sculpting humoral immunity through dengue vaccination to enhance protective immunity","volume":"3","author":"Crill","year":"2012","journal-title":"Front Immunol."},{"key":"B119","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"\u201cNeutralization and antibody-dependent enhancement of dengue viruses,\u201d","volume-title":"Advances in Virus Research","author":"Halstead","year":"2003"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s00253-018-8822-y","article-title":"Dengue viruses and promising envelope protein domain III-based vaccines","volume":"102","author":"Fahimi","year":"2018","journal-title":"Appl Microbiol Biotechnol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.virol.2009.06.037","article-title":"Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody","volume":"392","author":"Wahala","year":"2009","journal-title":"Virology."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3390\/v3122374","article-title":"The human antibody response to dengue virus infection","volume":"3","author":"Wahala","year":"2011","journal-title":"Viruses."},{"key":"B123","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.virol.2012.03.003","article-title":"Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo","volume":"429","author":"Williams","year":"2012","journal-title":"Virology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1099\/jgv.0.000278","article-title":"Secretion of dengue virus envelope protein ectodomain from mammalian cells is dependent on domain II serotype and affects the immune response upon DNA vaccination","volume":"96","author":"Campos","year":"2015","journal-title":"J Gen Virol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"e01706","DOI":"10.1128\/JVI.01706-16","article-title":"RPLP1 RPLP2 are essential flavivirus host factors that promote early viral protein accumulation","volume":"91","author":"Campos","year":"2017","journal-title":"J Virol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/JVI.02675-12","article-title":"Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection","volume":"87","author":"Rivino","year":"2013","journal-title":"J Virol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/infdis\/jiw309","article-title":"HLA-DRB1 alleles are associated with different magnitudes of dengue virus\u2013specific CD4 + T-cell responses","volume":"214","author":"Weiskopf","year":"2016","journal-title":"J Infect Dis."},{"key":"B128","doi-asserted-by":"publisher","first-page":"E4256","DOI":"10.1073\/pnas.1505956112","article-title":"Dengue virus infection elicits highly polarized CX3CR1 + cytotoxic CD4 + T cells associated with protective immunity","volume":"112","author":"Weiskopf","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B129","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1016\/S0264-410X(00)00543-0","article-title":"Immune responses and protection obtained with rotavirus VP6 DNA vaccines given by intramuscular injection","volume":"19","author":"Yang","year":"2001","journal-title":"Vaccine."},{"key":"B130","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12951-018-0337-2","article-title":"Chitosan-DNA nanoparticles enhanced the immunogenicity of multivalent DNA vaccination on mice against Trueperella pyogenes infection","volume":"16","author":"Huang","year":"2018","journal-title":"J Nanobiotechnology."},{"key":"B131","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/1096-9071(200010)62:2<224::aid-jmv14>3.0.co;2-c","article-title":"Dengue NS1-specific antibody responses: isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever","volume":"62","author":"Shu","year":"2000","journal-title":"J. Med. Virol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1128\/JVI.00316-08","article-title":"Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II","volume":"82","author":"Lai","year":"2008","journal-title":"J. Virol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1099\/0022-1317-68-3-853","article-title":"Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1","volume":"68","author":"Schlesinger","year":"1987","journal-title":"J Gen Viral."},{"key":"B134","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.4049\/jimmunol.1601523","article-title":"Therapeutic effects of monoclonal antibody against dengue virus NS1 in a STAT1 knockout mouse model of dengue infection","volume":"199","author":"Wan","year":"2017","journal-title":"J Immunol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","volume":"7","author":"Beatty","year":"2015","journal-title":"Sci Transl Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/infdis\/jiz081","article-title":"Magnitude and functionality of the NS1-specific antibody response elicited by a live-attenuated tetravalent dengue vaccine candidate","volume":"221","author":"Sharma","year":"2020","journal-title":"J Infect Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1016\/S0264-410X(03)00310-4","article-title":"Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice","volume":"21","author":"Wu","year":"2003","journal-title":"Vaccine."},{"key":"B138","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1023\/B:VIRU.0000012266.04871.ce","article-title":"Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus","volume":"28","author":"Timofeev","year":"2004","journal-title":"Virus Genes."},{"key":"B139","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.virol.2006.08.052","article-title":"DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice","volume":"358","author":"Costa","year":"2007","journal-title":"Virology."},{"key":"B140","doi-asserted-by":"publisher","first-page":"14626","DOI":"10.1073\/pnas.94.26.14626","article-title":"DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity","volume":"94","author":"Boyle","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B141","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/dna.1997.16.185","article-title":"Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization","volume":"16","author":"Inchauspe","year":"1997","journal-title":"DNA Cell Biol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1590\/S0100-879X1999000200011","article-title":"New vaccine strategies against enterotoxigenic Escherichia coli: I: DNA vaccines against the CFA\/I fimbrial adhesin","volume":"32","author":"Alves","year":"1999","journal-title":"Braz J Med Biol Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.vaccine.2005.07.059","article-title":"Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence","volume":"24","author":"Costa","year":"2006","journal-title":"Vaccine."},{"key":"B144","doi-asserted-by":"publisher","first-page":"e0004277","DOI":"10.1371\/journal.pntd.0004277","article-title":"Cooperation between CD4+ T cells and humoral immunity is critical for protection against dengue using a DNA vaccine based on the NS1 antigen","volume":"9","author":"Gon\u00e7alves","year":"2015","journal-title":"PLoS Negl Trop Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"e0163240","DOI":"10.1371\/journal.pone.0163240","article-title":"Aspects of T cell-mediated immunity induced in mice by a DNA vaccine based on the dengue-NS1 antigen after challenge by the intracerebral route","volume":"11","author":"Oliveira","year":"2016","journal-title":"PLoS ONE."},{"key":"B146","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamapediatrics.2016.3982","article-title":"Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians","volume":"171","author":"Moore","year":"2017","journal-title":"JAMA Pediatr."},{"key":"B147","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1038\/s41467-018-07008-0","article-title":"Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model","volume":"9","author":"Bailey","year":"2018","journal-title":"Nat Commun."},{"key":"B148","doi-asserted-by":"publisher","first-page":"eaax2388","DOI":"10.1126\/sciadv.aax2388","article-title":"NS1 DNA vaccination protects against Zika infection through T cell\u2013mediated immunity in immunocompetent mice","volume":"5","author":"Grubor-Bauk","year":"2019","journal-title":"Sci Adv."},{"key":"B149","doi-asserted-by":"publisher","first-page":"e00048","DOI":"10.1128\/JVI.00048-20","article-title":"Vesicular stomatitis virus and DNA vaccines expressing Zika virus nonstructural protein 1 induce substantial but not sterilizing protection against Zika virus infection","volume":"94","author":"Li","year":"2020","journal-title":"J Virol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"104521","DOI":"10.1016\/j.meegid.2020.104521","article-title":"NS1-based DNA vaccination confers mouse protective immunity against ZIKV challenge","volume":"85","author":"Zhan","year":"2020","journal-title":"Infect Genet Evol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0928-0197(98)00039-7","article-title":"Immune mediated and inherited defences against flaviviruses","volume":"10","author":"Brinton","year":"1998","journal-title":"Clin. Diagn. Virol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"e25685","DOI":"10.1371\/journal.pone.0025685","article-title":"Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines","volume":"6","author":"Costa","year":"2011","journal-title":"PLoS ONE."},{"key":"B153","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12929-016-0302-z","article-title":"Differential humoral and cellular immunity induced by vaccination using plasmid DNA and protein recombinant expressing the NS3 protein of dengue virus type 3","volume":"23","author":"Hurtado-Melgoza","year":"2016","journal-title":"J Biomed Sci."},{"key":"B154","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1016\/j.vaccine.2005.08.022","article-title":"DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus","volume":"24","author":"Costa","year":"2006","journal-title":"Vaccine"},{"key":"B155","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.molimm.2012.11.007","article-title":"Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM\/E and NS1: their immunity and protective efficacy in mice","volume":"54","author":"Lu","year":"2013","journal-title":"Mol Immunol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"558984","DOI":"10.3389\/fmedt.2020.558984","article-title":"Protective immunity to dengue virus induced by DNA vaccines encoding nonstructural proteins in a lethal challenge immunocompetent mouse model","volume":"2","author":"Alves","year":"2020","journal-title":"Front Med Technol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.vaccine.2010.11.014","article-title":"Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection","volume":"29","author":"Zheng","year":"2011","journal-title":"Vaccine"},{"key":"B158","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4269\/ajtmh.1998.58.144","article-title":"Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies","volume":"58","author":"Simmons","year":"1998","journal-title":"Am J Trop Med Hyg."},{"key":"B159","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4269\/ajtmh.2001.65.420","article-title":"Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine","volume":"65","author":"Simmons","year":"2001","journal-title":"Am J Trop Med Hyg."},{"key":"B160","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1128\/JVI.00284-06","article-title":"Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques","volume":"80","author":"Simmons","year":"2006","journal-title":"J Virol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1016\/j.vaccine.2016.03.108","article-title":"Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold\/DNA vaccine in non-human primates","volume":"34","author":"McBurney","year":"2016","journal-title":"Vaccine."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3892\/mmr.2014.2850","article-title":"Neutralizing antibodies respond to a bivalent dengue DNA vaccine or\/and a recombinant bivalent antigen","volume":"11","author":"Zhang","year":"2015","journal-title":"Mol Med Rep."},{"key":"B163","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/vim.2005.18.709","article-title":"DNA priming E and NS1 constructs\u2013homologous proteins boosting immunization strategy to improve immune response against dengue in mice","volume":"18","author":"Mellado-S\u00e1nchez","year":"2005","journal-title":"Viral Immunol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00705-010-0652-x","article-title":"A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model","volume":"155","author":"Mellado-S\u00e1nchez","year":"2010","journal-title":"Arch Virol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology."},{"key":"B166","first-page":"jiaa603","article-title":"Immunogenicity of a live-attenuated dengue vaccine using a heterologous prime-boost strategy in a phase 1 randomized clinical trial","volume-title":"J Infect Dis.","author":"Lin","year":"2020"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3389\/fmicb.2019.01113","article-title":"Vaccination with a single consensus envelope protein ectodomain sequence administered in a heterologous regimen induces tetravalent immune responses and protection against dengue viruses in mice","volume":"10","author":"Wang","year":"2019","journal-title":"Front Microbiol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/JVI.00996-07","article-title":"A heterologous DNA prime-venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques","volume":"81","author":"Chen","year":"2007","journal-title":"J Virol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4110\/in.2011.11.5.268","article-title":"Distinct humoral and cellular immunity induced by alternating prime-boost vaccination using plasmid DNA and live viral vector vaccines expressing the E protein of dengue virus type 2","volume":"11","author":"George","year":"2011","journal-title":"Immune Netw."},{"key":"B170","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-6750-7-10","article-title":"An adenovirus prime\/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes","volume":"7","author":"Khanam","year":"2007","journal-title":"BMC Biotechnol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-1702(01)00273-8","article-title":"Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses","volume":"79","author":"Caufour","year":"2001","journal-title":"Virus Res."},{"key":"B172","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-immunol-042617-053142","article-title":"Immune response to Dengue and Zika","volume":"36","author":"Ngono","year":"2018","journal-title":"Annu Rev Immunol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"7852","DOI":"10.1073\/pnas.1607931113","article-title":"Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus","volume":"113","author":"Priyamvada","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science."},{"key":"B175","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","article-title":"Vaccine protection against Zika virus from Brazil","volume":"536","author":"Larocca","year":"2016","journal-title":"Nature."},{"key":"B176","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet."},{"key":"B177","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.micinf.2018.03.001","article-title":"Rapid response to an emerging infectious disease - lessons learned from development of a synthetic DNA vaccine targeting Zika virus","volume":"20","author":"Kudchodkar","year":"2018","journal-title":"Micorbes Infect."},{"key":"B178","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/vaccines2030563","article-title":"Immunotherapy with an HIV-DNA vaccine in children and adults","volume":"2","author":"Palma","year":"2014","journal-title":"Vaccines."},{"key":"B179","doi-asserted-by":"publisher","first-page":"e0206837","DOI":"10.1371\/journal.pone.0206837","article-title":"DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: a phase 1 randomized clinical trial","volume":"13","author":"Houser","year":"2018","journal-title":"PLoS ONE."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fimmu.2019.01956","article-title":"Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus?","volume":"10","author":"Vald\u00e9s","year":"2019","journal-title":"Front Immunol."}],"container-title":["Frontiers in Medical Technology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2021.640964\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T04:56:36Z","timestamp":1618203396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2021.640964\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":180,"alternative-id":["10.3389\/fmedt.2021.640964"],"URL":"https:\/\/doi.org\/10.3389\/fmedt.2021.640964","relation":{},"ISSN":["2673-3129"],"issn-type":[{"value":"2673-3129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"article-number":"640964"}}